Genetic Analysis AS
Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market in the United States, Europe, and internationally. It offers GA-map, a platform for the analysis of the human gut microbiota; GA-map Dysbiosis Test that detects and characterizes dysbiosis; and GA-map Analyzer, a cloud-based software solution. The company also provides GA-map Discove… Read more
Genetic Analysis AS (GEAN) - Total Liabilities
Latest total liabilities as of September 2025: Nkr14.31 Million NOK
Based on the latest financial reports, Genetic Analysis AS (GEAN) has total liabilities worth Nkr14.31 Million NOK as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Genetic Analysis AS - Total Liabilities Trend (2020–2024)
This chart illustrates how Genetic Analysis AS's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Genetic Analysis AS Competitors by Total Liabilities
The table below lists competitors of Genetic Analysis AS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
JE Cleantech Holdings Ltd
NASDAQ:JCSE
|
USA | $13.31 Million |
|
Shrenik Limited
NSE:SHRENIK
|
India | ₹1.80 Billion |
|
WD-40 CO (WD1.SG)
STU:WD1
|
Germany | €218.51 Million |
|
Azincourt Uranium Inc
OTCQB:AZURF
|
USA | $341.08K |
|
Hall of Fame Resort Entertainment Co
NASDAQ:HOFV
|
USA | $325.72 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Genetic Analysis AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.48 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genetic Analysis AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genetic Analysis AS (2020–2024)
The table below shows the annual total liabilities of Genetic Analysis AS from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Nkr19.88 Million | -7.48% |
| 2023-12-31 | Nkr21.49 Million | +5.95% |
| 2022-12-31 | Nkr20.28 Million | +77.93% |
| 2021-12-31 | Nkr11.40 Million | +26.72% |
| 2020-12-31 | Nkr9.00 Million | -- |